153 related articles for article (PubMed ID: 35688842)
1. Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy.
Huang F; Li J; Wen X; Zhu B; Liu W; Wang J; Jiang H; Ding Y; Li D; Zhang X
Sci Rep; 2022 Jun; 12(1):9559. PubMed ID: 35688842
[TBL] [Abstract][Full Text] [Related]
2. Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.
Lin J; Lin Y; Huang Z; Li X
Comput Math Methods Med; 2020; 2020():8836493. PubMed ID: 33273963
[TBL] [Abstract][Full Text] [Related]
3. Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling.
Zou Z; Ou Q; Ren Y; Lv Q; Qin L; Zhao L; Su S; Wu X; Bao H; Wang A; Zhu D; Wang X; Shao YW; Liu B
Pigment Cell Melanoma Res; 2020 Jul; 33(4):601-611. PubMed ID: 31944535
[TBL] [Abstract][Full Text] [Related]
4. RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.
Jiang Y; Hu X; Wang Z; Zhang Q; Chen D; Zhao P
Invest New Drugs; 2024 Feb; 42(1):60-69. PubMed ID: 38071684
[TBL] [Abstract][Full Text] [Related]
5. Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.
Andrieu C; McNamee N; Larkin AM; Maguire A; Menon R; Mueller-Eisert J; Horgan N; Kennedy S; Gullo G; Crown J; Walsh N
Med Sci (Basel); 2022 May; 10(2):. PubMed ID: 35736346
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive clinicopathological and molecular analysis of primary malignant melanoma of the oesophagus.
Tsuyama S; Kohsaka S; Hayashi T; Suehara Y; Hashimoto T; Kajiyama Y; Tsurumaru M; Ueno T; Mano H; Yao T; Saito T
Histopathology; 2021 Jan; 78(2):240-251. PubMed ID: 32654197
[TBL] [Abstract][Full Text] [Related]
7. Clinical Application of Next-Generation Sequencing-Based Panel to
Park C; Kim M; Kim MJ; Kim H; Ock CY; Keam B; Kim TM; Kim DW; Kim JI; Heo DS
Mol Cancer Ther; 2020 Mar; 19(3):937-944. PubMed ID: 31826932
[TBL] [Abstract][Full Text] [Related]
8. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective.
Jung S; Johnson DB
Oncologist; 2022 Aug; 27(8):703-710. PubMed ID: 35640549
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
10. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy.
Li J; Smalley I; Chen Z; Wu JY; Phadke MS; Teer JK; Nguyen T; Karreth FA; Koomen JM; Sarnaik AA; Zager JS; Khushalani NI; Tarhini AA; Sondak VK; Rodriguez PC; Messina JL; Chen YA; Smalley KSM
Clin Cancer Res; 2022 May; 28(10):2131-2146. PubMed ID: 35247927
[TBL] [Abstract][Full Text] [Related]
11. Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma.
Mikoshiba A; Ashida A; Sakaizawa K; Kiniwa Y; Okuyama R
J Dermatol Sci; 2020 Mar; 97(3):172-178. PubMed ID: 31987696
[TBL] [Abstract][Full Text] [Related]
12. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
13. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
[TBL] [Abstract][Full Text] [Related]
14. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
15. Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas.
Edwards J; Ferguson PM; Lo SN; Pires da Silva I; Colebatch AJ; Lee H; Saw RPM; Thompson JF; Menzies AM; Long GV; Newell F; Pearson JV; Waddell N; Hayward NK; Johansson PA; Mann GJ; Scolyer RA; Palendira U; Wilmott JS
Cancer Immunol Res; 2020 Nov; 8(11):1346-1353. PubMed ID: 32917657
[TBL] [Abstract][Full Text] [Related]
16. Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance.
Horn S; Leonardelli S; Sucker A; Schadendorf D; Griewank KG; Paschen A
J Natl Cancer Inst; 2018 Jun; 110(6):677-681. PubMed ID: 29917141
[TBL] [Abstract][Full Text] [Related]
17. Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response.
Loo K; Gauvin G; Soliman I; Renzetti M; Deng M; Ross E; Luo B; Wu H; Reddy S; Olszanski AJ; Farma JM
Pigment Cell Melanoma Res; 2020 Nov; 33(6):878-888. PubMed ID: 32564504
[TBL] [Abstract][Full Text] [Related]
18. Different Response to Immunotherapy According to Melanoma Histologic Subtype.
Pala L; Conforti F; Pagan E; Bagnardi V; De Pas TM; Mazzarol G; Barberis M; Pennacchioli E; Orsolini G; Prestianni P; Zagami P; Nicolo' E; Patanè D; Saponara M; Queirolo P
J Immunother; 2022 Feb-Mar 01; 45(2):119-124. PubMed ID: 34908006
[TBL] [Abstract][Full Text] [Related]
19. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
20. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
